by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Imlunestrant alone or in combination with Verzenios improved patient-reported outcomes in ER+, HER2– advanced breast cancer following endocrine therapy. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Dr. Alexander Chehrazi-Raffle discusses findings from the phase 3 TiNivo-2 trial, designed to evaluate treatment with Fotivda in patients with metastatic renal cell carcinoma. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles As a cancer survivor I explain the importance of looking forward to life. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Adding Enhertu to Perjeta improved time without cancer growth versus standard care in advanced HER2-positive breast cancer, as per data from DESTINY-Breast09. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Participation in a structured exercise program following surgery and adjuvant chemo improved key survival end points in stage 3 and high-risk stage 2 CRC. Read More
by MM360 Staff | Jun 2, 2025 | Uncategorized
Source: CureToday articles Adding Imfinzi to fluorouracil-based chemo improved event-free survival and response rates in resectable gastric and gastroesophageal junction cancer. Read More